Biological Dynamics, Inc.
9381 Judicial Drive
Suite 120
San Diego
CA
92121
United States
41 articles about Biological Dynamics, Inc.
-
Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program
4/2/2024
Biological Dynamics Announces Expanding Adoption of ExoVerita™ Pro Under Early Access Program.
-
Biological Dynamics Announces Early Access Program to Its ExoVerita™ Pro Platform
11/8/2023
Biological Dynamics, Inc. announced the first opportunity for external users to access the company’s ExoVerita Pro, a cost-efficient, automated exosomal enrichment platform that delivers samples with best-in-class yields, purity, and reproducibility.
-
New Study Using Biological Dynamics’ ExoVerita Platform Validates Exosome Detection of Early-Stage Pancreatic Ductal Adenocarcinoma (PDAC)
10/19/2023
Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in Nature’s Communications Medicine titled “Development of a Blood-Based EV Classifier for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.”
-
Biological Dynamics to Share Data at 2023 Early Detection of Cancer Conference in London, Highlighting Value of Exosome-based Liquid Biopsy Assay in Detecting Pancreatic Cysts
10/5/2023
Biological Dynamics, Inc. will present a “lightning talk” as part of the “Understanding Pre-cancers to Enable Early Detection” track at the Early Detection of Cancer Conference, Oct. 10-12, 2023, in London.
-
Biological Dynamics and The Pancreatic Cancer Early Detection Consortium (PRECEDE) Collaborate to Improve Surveillance of Early Pancreatic Cancer
9/6/2023
Biological Dynamics, Inc. and the Pancreatic Cancer Early Detection (PRECEDE) Consortium have signed a multi-year agreement to partner on patient surveillance for early-stage pancreatic cancer using Biological Dynamics’ ExoVita Pancreas Assay, powered by the Verita platform.
-
New Study Demonstrates Efficient Exosome Isolation from Biological Fluids Using Proprietary Technology from Biological Dynamics
7/26/2023
Biological Dynamics, Inc., a leader in exosome-isolation technology for early disease detection, announced a newly published study in the journal Electrophoresis titled, “Enhancement of Dielectrophoresis-Based Particle Collection from High Conducting Fluids Due to Partial Electrode Insulation.”
-
Biological Dynamics to Highlight ExoLuminate Study for Early Detection of Pancreatic Cancer in High-Risk Populations at ASCO Annual Meeting
6/2/2023
Biological Dynamics, a leader in exosome-isolation technology for early disease detection, will present a poster featuring its ExoLuminate study design, currently enrolling, at The American Society of Clinical Oncology (ASCO), June 2-6, 2023 in Chicago, IL.
-
Biological Dynamics Case Report Published in Frontiers in Oncology Demonstrates Advancement in the Detection of Early-Stage Pancreatic Lesions
5/26/2023
Biological Dynamics announced the publication of a case report, “Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy,” in Frontiers in Oncology, highlighting the successful detection of early-stage pancreatic ductal adenocarcinoma lesions using its exosome liquid biopsy assay, ExoVitaTM Pancreas.
-
Biological Dynamics to Present Data at AACR Highlighting ExoVerita Platform-Enabled Earlier Detection of Pancreatic and Lung Cancers
4/14/2023
Biological Dynamics will present data showing how the company’s ExoVerita™ platform can be utilized for early detection of lung and pancreatic cancers at the American Association of Cancer Research annual meeting in Orlando, Fl., April 14-19.
-
Biological Dynamics and Oregon Health & Science University Collaborate on Early-Stage Pancreatic Cancer Detection Study
3/1/2023
Biological Dynamics, Inc., a company developing and commercializing its exosome-isolation ExoVerita™ platform for early disease diagnostics and other applications, announced its collaboration with the Brenden-Colson Center for Pancreatic Care at Oregon Health & Science University to study its ExoVita™ Pancreas assay.
-
Biological Dynamics launches ExoVita™ Pancreas and enrolls patients in ExoLuminate clinical trial
2/8/2023
Biological Dynamics, Inc., a company commercializing its exosome-isolation ExoVerita™ platform for early disease surveillance and other applications, today announced completion of the analytical and clinical validation of its lab developed test (LDT), ExoVita™ Pancreas in the company’s CLIA certified and CAP accredited laboratory.
-
Biological Dynamics, Perlmutter Cancer Center at NYU Langone Health collaborate on pancreatic cancer research
1/31/2023
Biological Dynamics, a company commercializing its exosome-isolation ExoVerita™ platform, announced a collaboration with the Perlmutter Cancer Center at NYU Langone Health to validate its application for the early detection of pancreatic ductal adenocarcinoma.
-
Biological Dynamics to deliver showcase presentation at Precision Medicine World Conference
1/24/2023
Biological Dynamics’ Medical Director, Harmeet Dhani, MD, MSc to present data demonstrating clinical utility of the ExoVerita™ exosome-isolation platform for detection of early-stage cancers.
-
Biological Dynamics Appoints Industry Veteran Peter Wulff as Chief Financial Officer
1/17/2023
Biological Dynamics, Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.
-
Biological Dynamics Files Legal Action Against Co-founders of EXOKĒRYX
1/4/2023
Biological Dynamics announced it has filed arbitration against two former employees, Richard Young and Bryan Rice, alleging that they have misappropriated Biological Dynamics’ proprietary technology to benefit their new company, EXOKĒRYX, Inc.
-
Biological Dynamics to participate at 2022 PRECEDE Biomarker Summit
12/7/2022
Biological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today that its Director of Medical Affairs, Harmeet Dhani, MD, MSc, will speak at the inaugural PRECEDE Early Detection Biomarker Summit in New York.
-
Biological Dynamics announces prospective clinical trial, ExoLuminate™
12/1/2022
Biological Dynamics, a company developing its exosome-isolation ExoVerita™ platform for early disease diagnostics, announced today it has received IRB approval and will soon begin to enroll patients in its ExoLuminate™ clinical study to validate its pancreatic ductal adenocarcinoma (PDAC) lab-developed test (LDT).
-
Biological Dynamics collaborates on clinical utility studies to examine the impact of its early pancreatic cancer detection assay
11/22/2022
Biological Dynamics, an exosome-isolation technology and early disease detection diagnostic company, today announced that it has partnered with both QURE Healthcare and Curta to explore how the company's assay for early detection of pancreatic ductal adenocarcinoma (PDAC) can improve patient outcomes, demonstrate the greatest value to clinicians, and enhance healthcare economics.
-
Biological Dynamics, an early detection disease management company, expands leadership
11/10/2022
Biological Dynamics, an exosome isolation technology and early disease detection company, announced new executive appointments to fuel its growth.
-
Biological Dynamics to Present at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit
8/3/2022
Biological Dynamics, Inc. today announced that the company will participate at the 2022 UBS Genomics 2.0 and MedTech Innovations Summit in Dana Point, California.